glp-1 agonists and sglt2 inhibitors Common systemic effects of either or GLP-1R Diabetic Agents, From Metformin to

Hales CM, Carroll MD, Fryar CD, Ogden CL

GLP-1 receptor This is the same receptor targeted by Wegovy and Mounjaro

doi: 10.1007/s00125-014-3231-y

Orforgliprons approval highlights both the growing role of GLP-1 therapies in weight loss and the potential for faster regulatory pathways, bringing new treatments to patients sooner

Methods: A comprehensive search of PubMed, Scopus, Web of Science, and Google Scholar identified 132 articles

With a single molecule approach, the ratio of activities of the constituents, however, will be fixed, whereas individual combination therapies present the potential benefit of being titratable to allow more optimal ratio between doses of the agonists